Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Patients with Type 2 Diabetes in the UK Setting

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.